Pfizer Inc. (NYSE:PFE) Shares Purchased by Chicago Capital LLC

Chicago Capital LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 3.5% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 75,197 shares of the biopharmaceutical company’s stock after acquiring an additional 2,575 shares during the quarter. Chicago Capital LLC’s holdings in Pfizer were worth $2,104,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Ceera Investments LLC grew its holdings in Pfizer by 6.4% during the second quarter. Ceera Investments LLC now owns 45,986 shares of the biopharmaceutical company’s stock valued at $1,287,000 after purchasing an additional 2,783 shares during the last quarter. Greystone Financial Group LLC boosted its stake in shares of Pfizer by 19.8% in the 2nd quarter. Greystone Financial Group LLC now owns 246,845 shares of the biopharmaceutical company’s stock valued at $6,907,000 after purchasing an additional 40,879 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Pfizer by 3,885.1% in the second quarter. Los Angeles Capital Management LLC now owns 1,899,435 shares of the biopharmaceutical company’s stock valued at $53,146,000 after buying an additional 1,851,772 shares in the last quarter. General American Investors Co. Inc. increased its stake in shares of Pfizer by 16.4% in the 2nd quarter. General American Investors Co. Inc. now owns 425,808 shares of the biopharmaceutical company’s stock valued at $11,914,000 after buying an additional 60,000 shares during the period. Finally, Wakefield Asset Management LLLP bought a new stake in shares of Pfizer during the second quarter worth approximately $454,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PFE. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, August 19th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Wells Fargo & Company increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Performance

NYSE:PFE traded up $0.05 on Friday, reaching $28.56. 31,214,484 shares of the company’s stock were exchanged, compared to its average volume of 38,328,773. The stock has a fifty day simple moving average of $29.06 and a 200-day simple moving average of $28.05. The firm has a market cap of $161.84 billion, a price-to-earnings ratio of -476.00, a P/E/G ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $34.64. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period last year, the firm earned $0.67 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.88%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s payout ratio is currently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.